The Eurozone economy grew 0.3% in Q4 2025, matching the previous quarter's pace and easing earlier recession fears. However, analysts warn that the euro's sharp 14.4% gain against the dollar over the past year threatens to undermine the competitiveness of European exports.
Iran has announced plans to designate the armed forces of European Union member states as terrorist organizations, a direct response to the EU's blacklisting of the Islamic Revolutionary Guard Corps. The escalation marks a new low in diplomatic relations and raises fears of further regional instability.
As the EU's landmark 'Next Generation' fund nears its final payout deadlines, its ambitious goal of modernizing the bloc's economy is being hampered by bureaucracy, skills gaps, and questions over long-term sustainability, despite pockets of innovation.
As geopolitical tensions and trade concerns weigh on sentiment, a screen of European equities uncovers potential value opportunities, with some companies trading at discounts of nearly 50% to their estimated intrinsic value.
The European Union has taken the unprecedented step of designating Iran's Islamic Revolutionary Guard Corps as a terrorist entity, triggering a sharp diplomatic crisis. Iran has denounced the move as illegal and politically motivated, vowing to respond.
As European indices face headwinds, a select group of small-cap companies are seeing executives put their own money on the line. We examine three firms where insider buying signals conviction amidst broader uncertainty.
As the STOXX Europe 600 stumbles under geopolitical and trade pressures, a focus on companies with significant insider ownership reveals where leadership is putting its own capital on the line. We examine three firms where high insider stakes coincide with robust growth forecasts.
After a significant rebound, ACADIA Pharmaceuticals (ACAD) shares present a conundrum for investors. While a discounted cash flow model suggests deep undervaluation, the stock's volatile history and mixed performance metrics demand a closer look at the underlying narrative.
Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.
Amidst a strategic merger with New Gold and a multi-year production expansion plan, Coeur Mining emerges as a compelling North American precious metals play. Analysts point to a significant gap between its current market valuation and underlying fundamentals.
Brussels-based clean transport group Transport & Environment warns that the European Commission's proposed easing of 2035 emissions targets may allow combustion-engine cars to make up half of new sales, marking a significant retreat from earlier climate ambitions.
Liberty Global, Europe's cable and mobile giant, has signed a five-year strategic partnership with Google Cloud to integrate Gemini AI and cloud tools across its operations, aiming to enhance TV platforms, automate services, and explore new revenue streams.
Investment firm Hussman Strategic Advisors has liquidated its entire stake in TG Therapeutics, a move that comes as the biotech's stock lags behind broader market gains despite reporting strong revenue growth for its flagship product.
In a stark New Year's address, German Chancellor Friedrich Merz warned that Europe faces an 'epochal break' in global order and must urgently strengthen its strategic autonomy, economic competitiveness, and defense capabilities to navigate rising geopolitical tensions.
Barclays PLC announces a series of senior leadership appointments across its securitized products, payments, and European operations, signaling strategic focus areas as it prepares to relocate its EU hub to Paris.
German Chancellor Friedrich Merz has called for urgent action to dismantle barriers and create a truly integrated European capital market, arguing it is essential for the bloc's economic competitiveness and to keep innovative firms from listing abroad.
Oppenheimer upgrades Relay Therapeutics (RLAY) to Outperform, citing the strength of its mutant-selective inhibitor pipeline and upcoming catalysts in the breast cancer treatment arena.
New clinical imaging data for Molecular Partners' experimental radiotherapeutic MP0712, targeting the DLL3 protein in cancers like small cell lung cancer, show favorable tumor targeting and healthy organ clearance. The company confirms its U.S. Phase I/II trial is now open for patient screening.
Major European neobanks like Revolut, Monzo, and bunq are renewing their push for a U.S. banking license, betting on regulatory shifts and market potential. Yet, the path is fraught with complexity, geopolitical uncertainty, and fierce competition.
The Supreme Court of British Columbia has granted final approval for Coeur Mining's acquisition of New Gold, moving the deal into its final regulatory phase. The transaction, poised to significantly expand Coeur's precious metals footprint, advances as the miner's stock shows considerable strength over the past year.
